Showing results (671-680 of 834) with videos related to

Sort By:
Pageof 84
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialNiels Jongs, Tom Greene, Glenn M Chertow, et al.
Clinical Kidney Journal|April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY populationNavdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Diabetes, Obesity & Metabolism|April 24, 2026
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY AnalysisJoão Sérgio Neves, Ana Rita Leite, Francisco Vasques-Nóvoa, et al.
Diabetes Care|August 16, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.
Diabetologia|February 1, 2025
Birthweight and risk of chronic kidney disease after a type 2 diabetes diagnosis in the DD2 cohortAleksander L Hansen, Christian F Christiansen, Charlotte Brøns, et al.
Kidney Medicine|September 27, 2023
Discordance Between Creatinine-Based and Cystatin C-Based Estimated GFR: Interpretation According to Performance Compared to Measured GFRYeli Wang, Ogechi M Adingwupu, Michael G Shlipak, et al.
Diabetes|November 22, 2023
Increased Subclinical Coronary Artery Pathology in Type 2 Diabetes With AlbuminuriaIda Kirstine Bull Rasmussen, Anne-Cathrine Skriver-Moeller, Rasmus Sejersten Ripa, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
American Journal of Nephrology|January 17, 2015
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathyLuis M Ruilope, Rajiv Agarwal, Juliana C Chan, et al.
Kidney International Reports|January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor TherapyPeter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Pageof 84